Beyond Borders: Global biotechnology report 2010

More documents

Recommendations

Info

New opportunities 24 Beyond borders Global biotechnology report 2010
Country profiles 25
Page 1: Beyond borders Global biotechnology
Page 4 and 5: Contents The new normal: the global
Page 6 and 7: The new normal
Page 8 and 9: Global introduction The new normal
Page 10 and 11: Of course, this is not a novel deve
Page 12 and 13: “Since by definition, increasing
Page 14 and 15: In both of these models, investors
Page 16 and 17: “For most of the history of the b
Page 18 and 19: A closer look Reforming US health c
Page 20 and 21: Perspectives for the new normal Foc
Page 22 and 23: Perspectives for the new normal Suc
Page 24 and 25: John Maraganore of Alnylam Pharmace
Page 26 and 27: Perspectives for the new normal The
Page 28 and 29: Using FIPNet to supercharge the inn
Page 32 and 33: Conversation on emerging markets Ne
Page 34 and 35: “The biggest challenge for Wester
Page 36 and 37: China year in review Accelerating r
Page 38 and 39: addition, the Government committed
Page 40 and 41: In 2009, overseas-listed Chinese bi
Page 42 and 43: India year in review Preparing for
Page 44 and 45: acquired US-based hybrid sorghum se
Page 46 and 47: Japanese biotech IPOs, 2009 Company
Page 48 and 49: drug application for Lurasidone to
Page 50 and 51: The year saw some examples of globa
Page 52 and 53: of today’s increasingly pragmatic
Page 54 and 55: Biotech will provide the technology
Page 56 and 57: Malaysia year in review A strategic
Page 58 and 59: A transformational year 52 Beyond b
Page 60 and 61: Financial performance A transformat
Page 62 and 63: explained by developments at a few
Page 64 and 65: Selected 2009 US biotechnology publ
Page 66 and 67: Growth rate Canada Behind the numbe
Page 68 and 69: Australian biotechnology at a glanc
Page 70 and 71: Financing A higher bar After a dism
Page 72 and 73: the pharmaceutical industry, as pha
Page 74 and 75: The final 2009 IPO to close in the
Page 76 and 77: The IPO market in Europe remains la
Page 78 and 79: Capital raised by Canadian province
Page 80 and 81:
developed countries — and whether
Page 82 and 83:
Deals A new landscape Given the rea
Page 84 and 85:
companies will not make any large u
Page 86 and 87:
with Elan (the judge agreed) the pa
Page 88 and 89:
Without Roche-Genentech, the value
Page 90 and 91:
total potential value of these tran
Page 92 and 93:
Products and pipeline Steady growth
Page 94 and 95:
FDA product approvals, 1996-2009 Nu
Page 96 and 97:
European Phase III pipeline by indi
Page 98 and 99:
A closer look Uncertain by design:
Page 100 and 101:
oral anti-diabetes medications Janu
Page 102 and 103:
Perspectives on personalized medici
Page 104 and 105:
Moderated by: Gil Forer Ernst & You
Page 106 and 107:
“I’m starting to see non-tradit
Page 108 and 109:
from infrastructure funds, but they
Page 110 and 111:
Data exhibit index 2 The not-quite-
Page 112 and 113:
Global biotechnology contacts Globa
Page 114:
Ernst & Young thought leadership Wa
show all

Beyond Borders: Global biotechnology report 2010

Create successful ePaper yourself

Delete template?

Save as template?